SEC Form 4 · accession 0001140361-15-004655

ARDELYX, INC. · ARDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — VP, Chemistry

Period of report

Feb 4, 2015

Accepted (ET)

Feb 6, 2015 · 6:40 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001437402

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Feb 4, 2015	M	6,416	$1.08	A	53,082	D
Common Stock	Feb 4, 2015	M	2,472	$1.08	A	55,554	D
Common Stock^F2	Feb 4, 2015	S	6,388	$16.0746	D	49,166	D
Common Stock^F3	Feb 4, 2015	S	2,500	$16.8204	D	46,666	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4	$1.08	Feb 4, 2015	M	6,416	D	—	Feb 17, 2021	Common Stock	6,416	0	D
Stock Option (Right to Buy)^F4	$1.08	Feb 4, 2015	M	2,472	D	—	Oct 26, 2020	Common Stock	2,472	0	D

F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 24, 2014.
F2This transaction was executed in multiple trades in prices ranging from $15.64 to $16.64, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3This transaction was executed in multiple trades in prices ranging from $16.74 to $17.055, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4The option is fully vested and exercisable.